How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension.
Title | How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Ntiloudi, D., Zanos S., Gatzoulis M. A., Karvounis H., & Giannakoulas G. |
Journal | Expert Rev Cardiovasc Ther |
Volume | 17 |
Issue | 1 |
Pagination | 11-18 |
Date Published | 2019 Jan |
ISSN | 1744-8344 |
Keywords | Heart Defects, Congenital, Humans, Hypertension, Pulmonary |
Abstract | INTRODUCTION: Patients with congenital heart disease (CHD), who develop pulmonary arterial hypertension (PAH), live longer, and have better quality of life compared to the past due to PAH-specific therapy and improved tertiary care. Areas covered: Clinical examination, objective assessment of functional capacity, natriuretic peptide levels, cardiac imaging, and hemodynamics all play a pivotal role in the evaluation, general care, and management of PAH-specific therapy. This review discusses the epidemiology and pathophysiology of PAH-CHD and provides hints for the optimal evaluation of these patients. Expert commentary: Further research should be performed in the field of PAH-CHD, as there are many of areas lacking evidence that should be addressed in the future. Networking, especially among the tertiary expert centers, could play a key role in this direction. |
DOI | 10.1080/14779072.2019.1550716 |
Alternate Journal | Expert Rev Cardiovasc Ther |
PubMed ID | 30457398 |